Target Name: ZNF740
NCBI ID: G283337
Review Report on ZNF740 Target / Biomarker Content of Review Report on ZNF740 Target / Biomarker
ZNF740
Other Name(s): MGC61706 | Zfp740 | zinc finger protein 740 | OriLyt TD-element-binding protein 7 | Zinc finger protein 740 | ZN740_HUMAN | TB7 | oriLyt TD-element-binding protein 7

ZNF740: A Potential Drug Target for Various Diseases

ZNF740 (MGC61706) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the ZNF family of proteins, which are known for their role in regulating gene expression and cell proliferation. ZNF740 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, ZNF740 has become a promising drug target and a focus of research in the field of molecular medicine.

The ZNF740 protein is composed of 21 kDa and contains 10 known protein domains, including a N-terminal transmembrane domain, a catalytic domain, and a C-terminal domain that is involved in protein-protein interactions. The N-terminal transmembrane domain is responsible for the protein's ability to interact with the cell membrane and is involved in the regulation of cellular signaling pathways. The catalytic domain is responsible for the protein's catalytic activity and is involved in the regulation of cellular metabolism. The C-terminal domain is involved in protein-protein interactions and is thought to play a role in the regulation of protein stability and degradation.

ZNF740 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of ZNF740 are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, ZNF740 has been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of cancer. For example, studies have shown that ZNF740 is involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell proliferation and survival.

As a result of its involvement in these processes, ZNF740 has become a focus of research in the field of molecular medicine. Researchers are interested in understanding how ZNF740 functions and how it can be used to treat various diseases. One approach to studying ZNF740 is through the use of techniques such as immunoprecipitation, RNA sequencing, and biochemical assays to determine the function of ZNF740 in these processes. Additionally, researchers are interested in studying the effects of drugs that can modulate ZNF740 function in order to develop new treatments for various diseases.

In conclusion, ZNF740 is a protein that is known for its role in the development and progression of various diseases. Its function is the subject of ongoing research in the field of molecular medicine, with a focus on understanding how it functions and how it can be used to treat various diseases. ZNF740 has the potential to be a valuable drug target for the treatment of a wide range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of ZNF740 in these processes and to develop new treatments for various diseases.

Protein Name: Zinc Finger Protein 740

Functions: May be involved in transcriptional regulation

The "ZNF740 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF740 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852 | ZNF853 | ZNF860 | ZNF862 | ZNF865 | ZNF875 | ZNF876P | ZNF878 | ZNF879 | ZNF880 | ZNF883 | ZNF887P | ZNF888 | ZNF890P | ZNF891 | ZNF90 | ZNF91